Citi Pharma Delivers Strong Financial Performance, Posting Higher Profit in First Quarter of FY2026-27
Citi Pharma Limited has reported an encouraging financial performance for the quarter ended September 30, 2026, demonstrating growth in profitability and improved earnings per share compared with the corresponding period last year.
According to the company’s unaudited consolidated financial statements, profit for the quarter increased to Rs. 248.79 million, compared with Rs. 203.69 million in the same quarter of 2025. This represents an increase of approximately 22.1%, reflecting an improvement in the company’s overall profitability.
Revenue and Gross Profit Show Positive Momentum
Citi Pharma recorded consolidated net sales of approximately Rs. 3.51 billion during the quarter ended September 30, 2026, compared with Rs. 3.37 billion in the corresponding period last year.
The company’s gross profit increased to Rs. 674.26 million from Rs. 518.97 million, indicating improved gross profitability despite higher operating costs.
This performance highlights the company’s ability to strengthen its gross earnings while maintaining revenue growth.
Operating Profit Records Significant Improvement
The company also reported an increase in operating profit, which reached Rs. 511.16 million during the quarter, compared with Rs. 420.36 million in the same period last year.
However, marketing and distribution expenses increased to Rs. 107.79 million from Rs. 48.43 million, while administrative and general expenses rose to Rs. 55.31 million from Rs. 50.19 million.
Despite these higher expenses, Citi Pharma managed to improve its operating profitability.
Earnings Per Share Increase to Rs. 1.09
One of the key highlights of the financial results was the improvement in earnings per share (EPS).
Citi Pharma reported EPS of Rs. 1.09 for the quarter ended September 30, 2026, compared with Rs. 0.89 in the corresponding quarter of the previous year.
The increase in EPS reflects stronger earnings generation and represents positive progress for shareholders.
Financial Position Remains Substantial
The company’s consolidated balance sheet also reflects a substantial asset base.
As of September 30, 2026, Citi Pharma reported total assets of approximately Rs. 17.97 billion, compared with Rs. 18.26 billion as of June 30, 2026.
Total equity stood at approximately Rs. 11.08 billion, while cash and bank balances reached approximately Rs. 270.81 million.
These figures provide insight into the company’s financial position and available resources as it continues its business operations.
Cash Flow and Business Investment
The consolidated cash flow statement showed net cash generated from operating activities of approximately Rs. 151.45 million during the quarter.
The company also reported investment-related cash outflows, including approximately Rs. 114.56 million for the purchase of property, plant and equipment and Rs. 21.32 million for capital work in progress.
These investments indicate continued spending on the company’s operational and infrastructure requirements.
Outlook for Investors
Citi Pharma’s latest quarterly results present a positive picture of its earnings performance. Growth in net sales, gross profit, operating profit and earnings per share demonstrates an improvement compared with the corresponding quarter of the previous year.
Nevertheless, investors will continue to monitor operating expenses, cash flows, financing costs and future revenue growth to assess the sustainability of the company’s performance.
The September 2026 quarterly results provide an encouraging starting point for Citi Pharma’s financial year 2026-27. The company’s ability to maintain profitability and strengthen its earnings will remain important factors in determining its future financial performance.
